PD-1 Biosimilar Races Towards Approval: What This Means For Oncology
Jeff Martin
February 18, 2025
*NEW VIDEO*
T Cell Engagers for Solid Tumors
From: Emerging Therapeutic Modalities in Oncology – 2025
- Jeff Martin
- Mar. 12th, 2025
*NEW VIDEO*
T Cell Engagers for Solid Tumors
From: Emerging Therapeutic Modalities in Oncology – 2025
- Jeff Martin
- Mar. 12th, 2025
Oncoleader Newsletter
At Oncoleader, we talk oncology biotech. Subscribe to get updated on our latest insights, technology deep dives, and in-depth breakdowns on all the latest in oncology biotech.
RECENT ARTICLES
Allogene’s Allogeneic CAR-T Show Promise in Phase 1: A Breakdown
Jeff Martin
February 16, 2025
AbbVie and Xilio Partner Up to Advance Tumor-Activated T Cell Engagers
Jeff Martin
February 14, 2025
NKGen’s FDA Fast Track & Positive Alzheimer’s Results: A Win For NK Cells
Jeff Martin
February 13, 2025
Oncoleader Newsletter
At Oncoleader, we talk oncology biotech. Subscribe to get updated on our latest insights, technology deep dives, and in-depth breakdowns on all the latest in oncology biotech.
*NEW VIDEO SERIES*
Emerging Therapeutic Modalities in Oncology
(ETiO 2025)
- Jeff Martin
- Feb. 17th, 2025
ETiO 2025 Video Series
Emerging Trends in Oncology: Video Breakdowns
Jeff Martin
November 19, 2024
Oncoleader Newsletter
At Oncoleader, we talk oncology biotech. Subscribe to get updated on our latest insights, technology deep dives, and in-depth breakdowns on all the latest in oncology biotech.
*FULL VIDEO COURSE*
Cancer Immunology: The Core Concepts
- Jeff Martin
- Jan. 1, 2025
Oncoleader Newsletter
At Oncoleader, we talk oncology biotech. Subscribe to get updated on our latest insights, technology deep dives, and in-depth breakdowns on all the latest in oncology biotech.
